|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
86,568,000 |
Market
Cap: |
1.34(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$5.79 - $20.32 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 24.2 |
Insider 3/6 Months : 24.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
6,579,493 |
6,611,050 |
8,088,052 |
Total Buy Value |
$0 |
$45,086,736 |
$45,289,581 |
$53,421,765 |
Total People Bought |
0 |
3 |
3 |
4 |
Total Buy Transactions |
0 |
3 |
4 |
9 |
Total Shares Sold |
54,240 |
103,816 |
107,114 |
108,208 |
Total Sell Value |
$895,306 |
$1,780,570 |
$1,802,142 |
$1,812,515 |
Total People Sold |
5 |
5 |
5 |
6 |
Total Sell Transactions |
10 |
12 |
14 |
15 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Myles Edward H |
COO & CFO |
|
2024-02-16 |
4 |
S |
$15.74 |
$74,686 |
D/D |
(4,744) |
210,976 |
|
5% |
|
Parlavecchio Caryn |
CHRO |
|
2024-02-16 |
4 |
S |
$15.74 |
$59,053 |
D/D |
(3,751) |
157,744 |
|
5% |
|
Backstrom Jay T. |
CHIEF EXECUTIVE OFFICER |
|
2024-02-16 |
4 |
S |
$15.74 |
$182,842 |
D/D |
(11,614) |
352,671 |
|
5% |
|
Ho Junlin |
GENERAL COUNSEL |
|
2024-02-16 |
4 |
S |
$15.74 |
$54,928 |
D/D |
(3,489) |
208,771 |
|
5% |
|
Qatanani Mo |
CHIEF SCIENTIFIC OFFICER |
|
2024-02-16 |
4 |
S |
$15.74 |
$39,547 |
D/D |
(2,512) |
147,019 |
|
5% |
|
Backstrom Jay T. |
CHIEF EXECUTIVE OFFICER |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
214,285 |
364,285 |
|
- |
|
Ho Junlin |
GENERAL COUNSEL |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
57,855 |
212,260 |
|
- |
|
Myles Edward H |
COO & CFO |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
53,570 |
215,720 |
|
- |
|
Marantz Jing L. |
CHIEF MEDICAL OFFICER |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
72,855 |
72,855 |
|
- |
|
Parlavecchio Caryn |
CHRO |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
47,145 |
161,495 |
|
- |
|
Sacco Tracey |
CHIEF COMMERCIAL OFFICER |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
49,285 |
49,285 |
|
- |
|
Qatanani Mo |
CHIEF SCIENTIFIC OFFICER |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
70,715 |
149,531 |
|
- |
|
Parlavecchio Caryn |
CHRO |
|
2024-01-16 |
4 |
S |
$15.93 |
$45,381 |
D/D |
(2,849) |
114,350 |
|
6% |
|
Ho Junlin |
GENERAL COUNSEL |
|
2024-01-16 |
4 |
S |
$15.93 |
$66,677 |
D/D |
(4,186) |
154,405 |
|
6% |
|
Myles Edward H |
COO & CFO |
|
2024-01-16 |
4 |
S |
$15.93 |
$105,670 |
D/D |
(6,634) |
162,150 |
|
6% |
|
Qatanani Mo |
SVP AND HEAD OF RESEARCH |
|
2024-01-16 |
4 |
S |
$15.93 |
$31,889 |
D/D |
(2,002) |
78,816 |
|
6% |
|
Myles Edward H |
COO & CFO |
|
2023-12-29 |
4 |
AS |
$18.82 |
$234,633 |
D/D |
(12,459) |
168,784 |
|
-13% |
|
Myles Edward H |
COO & CFO |
|
2023-12-29 |
4 |
OE |
$4.86 |
$60,551 |
D/D |
12,459 |
181,243 |
|
- |
|
Nashat Amir |
|
|
2023-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
21,333 |
25,506 |
|
- |
|
Burow Kristina |
Director |
|
2023-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
5,339 |
5,339 |
|
- |
|
Burow Kristina |
Director |
|
2023-12-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(291,906) |
2,345,711 |
|
- |
|
Qatanani Mo |
SVP AND HEAD OF RESEARCH |
|
2023-12-14 |
4 |
S |
$18.18 |
$448,444 |
D/D |
(24,662) |
80,818 |
|
19% |
|
Qatanani Mo |
SVP AND HEAD OF RESEARCH |
|
2023-12-14 |
4 |
OE |
$10.00 |
$84,370 |
D/D |
8,437 |
105,480 |
|
- |
|
Nashat Amir |
|
|
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
26,265 |
46,839 |
|
- |
|
Nashat Amir |
|
|
2023-12-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,197,068) |
0 |
|
- |
|
119 Records found
|
|
Page 1 of 5 |
|
|